Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials-Reference-Cited by-同舟云学术

Survival after neoadjuvant therapy with trastuzumab–lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials

Published:2022-04 Issue:2 Volume:7 Page:100433
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Guarneri V.,Griguolo G.,Miglietta F.,Conte P.F.,Dieci M.V.,Girardi F.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference25 articles.

1. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis;Cortazar;Lancet,2014

2. Trastuzumab containing regimens for early breast cancer;Moja;Cochrane Database Syst Rev,2012

3. Trastuzumab-containing regimens for metastatic breast cancer;Balduzzi;Cochrane Database Syst Rev,2014

4. Primary systemic therapy for operable breast cancer: a review of clinical trials and perspectives;Guarneri;Cancer Lett,2007

5. Eighth Edition of the AJCC cancer staging manual: breast cancer;Giuliano;Breast Oncol,2018

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tailoring Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Recent Advances and Strategies;JCO Oncology Practice;2024-08

2. Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka;Scientific Reports;2024-07-20

3. Distinct ER and PR expression patterns significantly affect the clinical outcomes of early HER2-positive breast cancer: A real-world analysis of 871 patients treated with neoadjuvant therapy;The Breast;2024-06

4. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer;JAMA Oncology;2024-05-01

5. Safety and efficacy of pyrotinib for HER‑2‑positive breast cancer in the neoadjuvant setting: A systematic review and meta‑analysis;Oncology Letters;2024-03-04